Wegovy and Sexual Function: What the Evidence Actually Shows

Wegovy is the brand name for semaglutide 2.4 mg, a GLP-1 receptor agonist given by injection and approved by the FDA to help adults and some adolescents with obesity or overweight-related conditions manage their weight over the long term. Semaglutide is also marketed as Ozempic for type 2 diabetes, though that formulation uses lower doses. The FDA approval for Wegovy does not include any indication for treating sexual dysfunction, reduced sex drive, or low testosterone. Sexual function changes linked to Wegovy may stem from weight loss and improved metabolism, along with possible but unconfirmed direct effects of GLP-1 signaling on reproductive structures.

The core answer: Wegovy has no FDA-labeled effect on sexual function in either direction. The best-supported effect is indirect: clinically meaningful weight loss (the kind produced in the pivotal STEP-1 trial) is biologically plausible to improve androgen status, vascular function, and self-reported sexual satisfaction over many months, while the first weeks of treatment can transiently reduce libido through nausea and appetite suppression rather than through any hormonal mechanism. No large randomized trial of semaglutide 2.4 mg has used a validated sexual function instrument (such as the IIEF or FSFI) as a primary or pre-specified secondary outcome, so claims about the size of any sexual-function benefit are inference from related literature, not a direct trial finding.

What is established, what is plausible, and what is not established

Established, from the FDA label and the pivotal trial:

• Wegovy is not FDA-approved to treat sexual dysfunction of any kind.
• In the STEP-1 trial, semaglutide 2.4 mg produced substantially greater weight loss than placebo over 68 weeks, and nausea was common, especially during dose escalation. These topline efficacy and safety figures are in the FDA-approved prescribing information. (FDA label, PDF)
• Semaglutide is contraindicated in pregnancy, and effective contraception is recommended for people who can become pregnant while on treatment.
• GLP-1 receptors are expressed outside the gut and pancreas, including in parts of the brain that regulate appetite and, in animal and tissue studies, in some reproductive organs. This is biology, not a demonstrated clinical effect on human sexual function.

Plausible but not directly demonstrated in semaglutide trials:

• Weight loss lowers sex-hormone-binding globulin and raises free testosterone in men with obesity; this relationship is well described in the general obesity and bariatric-surgery literature. Whether it translates into a specific, reproducible libido or erectile-function benefit at the weight-loss magnitude Wegovy produces has not been tested with a validated instrument in a semaglutide trial.
• Reduced systemic inflammation and improved endothelial function with weight loss are plausible contributors to improved erectile and clitoral blood flow, based on general cardiometabolic and obesity-medicine literature, not semaglutide-specific sexual-function trials.
• Bariatric surgery data, which is the closest available proxy because surgery produces weight loss of a similar or larger magnitude, has reported improvements in erectile function and female sexual function scores after significant weight loss. Using this literature to predict semaglutide's effect requires treating it as an analogy, not equivalent evidence, and the specific papers commonly cited for this comparison need to be checked against the primary source before being used for patient-facing numeric claims.

Not established:

• No precise, verified effect size exists for how much semaglutide 2.4 mg changes IIEF, FSFI, or free testosterone in a general population. Numbers that circulate online (specific point changes, specific nmol/L values) trace back to studies of weight loss in general or to bariatric surgery, not to a semaglutide-specific trial with a validated sexual-function endpoint, and some of those secondary citations could not be independently verified for this article. Treat any such number you encounter as an estimate requiring a direct check of the underlying paper, not a settled fact.
• Whether direct GLP-1 receptor activity in gonadal tissue matters clinically in humans, separate from weight loss, is unresolved.
• A reported pharmacovigilance signal for decreased libido with semaglutide exists in adverse-event databases, but adverse-event reports are not adjusted for nausea, concurrent medications, or baseline sexual function, and disproportionality alone does not establish causation.

Why the first weeks can feel worse before anything improves

The dose-escalation phase of Wegovy starts at 0.25 mg weekly and increases roughly every four weeks toward the 2.4 mg maintenance dose, with slower escalation allowed for tolerability. Nausea is one of the most common side effects during this phase, and it is reasonable to expect appetite suppression and reduced general energy alongside it. A drop in sexual interest during these first weeks is more plausibly explained by nausea, fatigue, and caloric restriction than by any hormonal change, since meaningful weight loss and the metabolic shifts that could affect testosterone or vascular function take longer to accumulate. Patients who stop paying attention to sexual function during this phase, or who assume a temporary dip is permanent, may draw the wrong conclusion about the drug.

Men: testosterone, erectile function, and the hypogonadism question

Obesity is associated with a pattern often called functional or hypogonadotropic hypogonadism: low testosterone from suppressed pituitary signaling and increased peripheral conversion of testosterone to estradiol in fat tissue, rather than primary testicular failure. This form of low testosterone is the kind most plausibly improved by weight loss, because the underlying driver (excess adiposity) is being treated. Endocrine Society guidance on male hypogonadism advises reassessing testosterone after clinically significant weight loss before committing a patient to testosterone replacement therapy, since functional hypogonadism can resolve without it. That guideline also defines the testosterone threshold and confirmatory testing generally used to diagnose hypogonadism requiring treatment; the exact threshold is a clinical detail your prescriber should apply directly from the current guideline rather than from a secondhand summary.

Distinguishing functional from primary hypogonadism matters practically. If testosterone stays low despite substantial weight loss, checking LH and FSH helps separate a pituitary/hypothalamic problem or reversible obesity-related suppression from primary testicular failure, which will not respond to weight loss. Erectile dysfunction in men over 40 is frequently a vascular problem, and the same weight-loss-driven improvements in insulin sensitivity, inflammation, and endothelial function that plausibly help testosterone are also plausible contributors to erectile function, though again, this has not been measured directly in a Wegovy trial.

Women: hormonal balance and the FSFI domains

In women with obesity, the hormonal picture is different from men's. Excess adipose tissue increases peripheral estrogen production while insulin resistance can drive ovarian androgen production, producing an altered balance between estrogen, free androgens, and sex-hormone-binding globulin. Weight loss in this population is associated with improvements across the domains measured by the Female Sexual Function Index (desire, arousal, lubrication, orgasm, satisfaction, and pain) in general obesity and dietary-intervention literature. Whether semaglutide-driven weight loss produces the same pattern has not been tested with FSFI as a study outcome in a semaglutide trial. Women with PCOS may see compounding benefits from improved insulin sensitivity and more regular cycles, and off-label use of semaglutide in PCOS is increasingly common in practice, though no phase 3 trial has enrolled a PCOS-specific cohort to confirm sexual-function outcomes.

When sexual function does not improve

Not everyone who loses weight on Wegovy will see sexual function change, and persistence of dysfunction after significant, sustained weight loss deserves its own workup rather than an assumption that "the drug just doesn't help." Reasonable differentials include:

• Primary hypogonadism (testicular failure, Klinefelter syndrome, prior chemotherapy) will not respond to weight loss; elevated FSH with low testosterone points here.
• Concurrent medications with well-established sexual side effects, including SSRIs, some beta-blockers, and antipsychotics, can mask or override any benefit from weight loss. Medication reconciliation is a reasonable step before assuming semaglutide has failed to help.
• Psychosocial and relationship factors contribute to sexual dysfunction independent of weight or hormones, and body-image change during rapid weight loss can affect sexual confidence in either direction.
• PDE5 inhibitors (sildenafil, tadalafil) have no known pharmacokinetic interaction with semaglutide and can be used concurrently if erectile dysfunction persists during treatment.

Decision guide: sexual function on Wegovy, by phase and finding

This table is a structured way to think through the question, not a substitute for an individualized evaluation. Testosterone thresholds, TRT decisions, and medication changes should be made by the treating clinician using current guidelines and the patient's full history.

Monitoring that a prescriber might reasonably discuss

A monitoring approach some clinicians use, without this being a formal guideline requirement specific to sexual function:

• Baseline conversation about expected phases (early dip, later possible improvement) before starting treatment
• Weight-loss checkpoint around week 16, which is also when the FDA label suggests reassessing overall treatment response
• For men with baseline concerns: testosterone and related labs at baseline and again after significant weight loss, since functional hypogonadism can resolve and change a testosterone-replacement decision
• For women with PCOS or menstrual irregularity: cycle tracking and re-evaluation if irregularity persists past about 6 months
• Direct, repeated questions about sexual function at follow-up visits, since patients often do not raise this topic unprompted in general obesity-medicine practice

What this means for a patient deciding whether to bring it up

If sexual function matters to your decision to start or continue Wegovy, it is reasonable to raise it directly with your prescriber before starting, so you know what to expect in the first three months versus what might change later, and so any pre-existing sexual dysfunction, medication effects, or hormonal issues are identified before they get attributed incorrectly to the drug. A temporary dip early in treatment is not, on its own, a reason to assume the medication will make things worse long term, and a lack of improvement after many months of sustained weight loss is a reasonable trigger for further evaluation rather than an assumption that nothing more can be done.

When to seek prompt care

Sudden, severe pelvic or genital pain, priapism (a prolonged, painful erection), signs of a pregnancy while on a medication contraindicated in pregnancy, or new severe depression or suicidal thinking associated with body-image or mood changes during weight loss all warrant prompt medical attention rather than waiting for a routine follow-up.

This article reviews the likely biological pathways and relevant evidence from obesity medicine alongside the actual language in Wegovy's FDA label. This article is not a substitute for personalized medical assessment. Specific numerical claims about testosterone shifts, IIEF or FSFI score changes, and adverse-event frequencies encountered during research for this article could not be traced to a confirmed original source and are therefore presented in general terms; readers who want to cite precise figures should verify them in the primary literature.

Reference used directly in this draft: US Food and Drug Administration. Wegovy (semaglutide) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf